Year All2024202320222021 Zevra Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference 09-05-2023 Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product 08-31-2023 Zevra Therapeutics Reports Corporate Updates and Second Quarter 2023 Financial Results 08-14-2023 Zevra Therapeutics Appoints Thomas Anderson to Board of Directors and Announces Retirement of Matthew R. Plooster 08-07-2023 Zevra Therapeutics to Report Second Quarter 2023 Results on August 14, 2023 08-02-2023 Zevra Therapeutics to Participate in the 2023 NNPDF Family Support and Medical Conference 07-19-2023 Zevra Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023 06-20-2023 Zevra Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest 06-13-2023 Zevra Therapeutics Presents Design of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH) at Beyond Sleepy 2023 06-03-2023 Zevra Therapeutics Reports Corporate Updates and First Quarter 2023 Financial Results 05-15-2023
Zevra Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference 09-05-2023
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product 08-31-2023
Zevra Therapeutics Appoints Thomas Anderson to Board of Directors and Announces Retirement of Matthew R. Plooster 08-07-2023
Zevra Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023 06-20-2023
Zevra Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest 06-13-2023
Zevra Therapeutics Presents Design of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH) at Beyond Sleepy 2023 06-03-2023
